Clinical trial · Observational
Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer
Hybrid Techniques Combining Hypofractionated Whole Breast Radiotherapy With Concomitant Tumor Bed Boost in Patients With Breast Cancer
NCT06984250CI-TRIAL-00090037HFCBBrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Hypofractionated breast radiotherapy with concomitant tumor bed boost for early breast cancer or ductal breast carcinoma in situ after partial mastectomy
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ductal Breast Carcinoma In Situ | Breast Ductal Carcinoma In Situ | ALIAS | 0.90 |
| Early Breast Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hypofractionated Radiation Therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- CBB
- description
- Hypofractionated breast radiotherapy following partial mastectomy in patients with early breast cancer or ductal breast carcinoma in situ
- interventionNames
- Radiation: Hypofractionated Radiation Therapy
Primary outcomes (1)
- measure
- Ipsilateral breast tumor recurrence
- timeFrame
- From enrollment to the end of treatment at 2 years
- description
- The time from the date of completion of radiotherapy to the date of ipsilateral breast recurrence or death, whichever occurs first. Unit of Measure: Time-to-event (months)
Secondary outcomes (4)
- measure
- Early Phase Acute Skin Toxicity
- timeFrame
- Up to 3 months following completion of radiotherapy
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Female patients with histologically confirmed early-stage breast cancer (T1-2 and N0-1) or ductal carcinoma in situ (DCIS). * Patients undergoing breast-conserving surgery * Age ≥ 20 years * Karnofsky Performance Status (KPS) ≥70% * Life expectancy ≥ 5 years * Adequate renal and hepatic function Exclusion Criteria: * Pregnant patients * Patients requiring re-irradiation of the thoracic region
References
Publications (0)
Data not yet available
No reference posted for this study.